DDR1 and neoplasm: At ~4–6 weeks post tumor inoculation, mice harboring CD167a-overexpressing xenograft tumors started exhibiting a notable loss in body weight when compared to vector controls, which became statistically significant at 10–12 weeks (Fig. 3b, control n = 7, CD167a n = 7).